78 related articles for article (PubMed ID: 17283149)
1. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments.
Lepelletier Y; Camara-Clayette V; Jin H; Hermant A; Coulon S; Dussiot M; Arcos-Fajardo M; Baude C; Canionni D; Delarue R; Brousse N; Benaroch P; Benhamou M; Ribrag V; Monteiro RC; Moura IC; Hermine O
Cancer Res; 2007 Feb; 67(3):1145-54. PubMed ID: 17283149
[TBL] [Abstract][Full Text] [Related]
2. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas.
Crépin R; Goenaga AL; Jullienne B; Bougherara H; Legay C; Benihoud K; Marks JD; Poul MA
Cancer Res; 2010 Jul; 70(13):5497-506. PubMed ID: 20530676
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma.
Park IW; Reddy MV; Reddy EP; Groopman JE
Oncogene; 2007 Aug; 26(38):5635-42. PubMed ID: 17369860
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo.
Qian Z; Zhang L; Cai Z; Sun L; Wang H; Yi Q; Wang M
Leuk Res; 2011 Mar; 35(3):380-6. PubMed ID: 21047686
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody.
Callens C; Moura IC; Lepelletier Y; Coulon S; Renand A; Dussiot M; Ghez D; Benhamou M; Monteiro RC; Bazarbachi A; Hermine O
Leukemia; 2008 Jan; 22(1):42-8. PubMed ID: 17898788
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
[TBL] [Abstract][Full Text] [Related]
9. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
11. CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines.
Jin Z; Teramoto N; Hayashi K; Liu YX; Jin G; Oka T; Takahashi K; Yoshino T; Akagi T
Anticancer Res; 2004; 24(2B):691-7. PubMed ID: 15161013
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.
De Milito A; Iessi E; Logozzi M; Lozupone F; Spada M; Marino ML; Federici C; Perdicchio M; Matarrese P; Lugini L; Nilsson A; Fais S
Cancer Res; 2007 Jun; 67(11):5408-17. PubMed ID: 17545622
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
[TBL] [Abstract][Full Text] [Related]
15. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice.
Estella-Hermoso de Mendoza A; Campanero MA; de la Iglesia-Vicente J; Gajate C; Mollinedo F; Blanco-Prieto MJ
Clin Cancer Res; 2009 Feb; 15(3):858-64. PubMed ID: 19188156
[TBL] [Abstract][Full Text] [Related]
18. Cell-death-inducing monoclonal antibodies raised against DT40 tumor cells: identification of chicken transferrin receptor as a novel cell-death receptor.
Ohno Y; Yagi H; Nakamura M; Masuko K; Hashimoto Y; Masuko T
Cancer Sci; 2008 May; 99(5):894-900. PubMed ID: 18294284
[TBL] [Abstract][Full Text] [Related]
19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
20. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.
Takheaw N; Sittithumcharee G; Kariya R; Kasinrerk W; Okada S
Cancer Immunol Immunother; 2021 Jun; 70(6):1557-1567. PubMed ID: 33215253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
